NO20003422D0 - Arylfusjonerte azapolycykliske forbindelser - Google Patents

Arylfusjonerte azapolycykliske forbindelser

Info

Publication number
NO20003422D0
NO20003422D0 NO20003422A NO20003422A NO20003422D0 NO 20003422 D0 NO20003422 D0 NO 20003422D0 NO 20003422 A NO20003422 A NO 20003422A NO 20003422 A NO20003422 A NO 20003422A NO 20003422 D0 NO20003422 D0 NO 20003422D0
Authority
NO
Norway
Prior art keywords
aryl
fused azapolycyclic
azapolycyclic compounds
compounds
fused
Prior art date
Application number
NO20003422A
Other languages
English (en)
Other versions
NO20003422L (no
NO319115B1 (no
Inventor
Jotham Wadsworth Coe
Paige Roanne Palmer Brooks
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003422(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20003422D0 publication Critical patent/NO20003422D0/no
Publication of NO20003422L publication Critical patent/NO20003422L/no
Publication of NO319115B1 publication Critical patent/NO319115B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20003422A 1997-12-31 2000-06-30 Arylfusjonerte azapolycykliske forbindelser, anvendelse derav samt farmasoytiske sammensetninger. NO319115B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en) 1997-12-31 1998-11-13 Aryl fused azapolycyclic compounds

Publications (3)

Publication Number Publication Date
NO20003422D0 true NO20003422D0 (no) 2000-06-30
NO20003422L NO20003422L (no) 2000-08-29
NO319115B1 NO319115B1 (no) 2005-06-20

Family

ID=22094096

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003422A NO319115B1 (no) 1997-12-31 2000-06-30 Arylfusjonerte azapolycykliske forbindelser, anvendelse derav samt farmasoytiske sammensetninger.
NO2006016C NO2006016I1 (no) 1997-12-31 2006-11-17 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2006016C NO2006016I1 (no) 1997-12-31 2006-11-17 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat

Country Status (52)

Country Link
US (6) US6410550B1 (no)
EP (2) EP1044189B2 (no)
JP (1) JP3550359B2 (no)
KR (1) KR100408138B1 (no)
CN (2) CN1715280A (no)
AP (1) AP1170A (no)
AR (1) AR017967A1 (no)
AT (1) ATE386024T1 (no)
AU (1) AU753389C (no)
BG (1) BG65058B1 (no)
BR (2) BR9814592B1 (no)
CA (1) CA2316921C (no)
CO (1) CO4810373A1 (no)
CY (2) CY1107391T1 (no)
CZ (1) CZ301925B6 (no)
DE (2) DE122008000038I1 (no)
DK (1) DK1044189T4 (no)
DZ (1) DZ2697A1 (no)
EA (1) EA003190B1 (no)
EG (1) EG23816A (no)
ES (1) ES2301210T5 (no)
FR (1) FR08C0039I2 (no)
GT (2) GT199800200A (no)
HK (1) HK1031878A1 (no)
HN (1) HN1998000177A (no)
HR (2) HRP20000445B1 (no)
HU (2) HU230297B1 (no)
IL (2) IL136727A0 (no)
IS (1) IS5514A (no)
LU (1) LU91442I2 (no)
MA (1) MA26589A1 (no)
ME (1) ME00459B (no)
MY (1) MY118163A (no)
NL (1) NL300355I2 (no)
NO (2) NO319115B1 (no)
NZ (1) NZ504482A (no)
OA (1) OA11428A (no)
PA (1) PA8463901A1 (no)
PE (1) PE20000053A1 (no)
PL (1) PL209404B1 (no)
PT (1) PT1044189E (no)
RS (1) RS50069B (no)
SA (1) SA99191123B1 (no)
SG (1) SG102686A1 (no)
SI (1) SI1044189T2 (no)
SK (1) SK286886B6 (no)
TN (1) TNSN98237A1 (no)
TR (1) TR200001840T2 (no)
TW (1) TW513412B (no)
UA (1) UA66825C2 (no)
WO (1) WO1999035131A1 (no)
ZA (1) ZA9811911B (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
WO2001008684A1 (en) 1999-07-28 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
MXPA03010365A (es) 2001-05-14 2004-03-16 Pfizer Prod Inc Sal citrato de 5,7,14-triazatetraciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma.
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
MXPA04003807A (es) * 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
AU2002365314A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Aryl fused azapolycyclic compounds
CA2475972C (en) * 2002-02-14 2017-07-11 Felix Hausch Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
EP1961737A1 (en) * 2002-11-20 2008-08-27 Pfizer Products Inc. Indan-1,3-carbodinitrile dervatives
DK1563300T3 (da) * 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
RU2284319C2 (ru) * 2002-11-25 2006-09-27 Пфайзер Продактс Инк. Усовершенствованный способ получения 1,3-замещенных инденов
AU2004203983A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
MXPA05013084A (es) * 2003-06-04 2006-03-02 Pfizer Prod Inc Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
BRPI0412712A (pt) * 2003-07-21 2006-09-26 Pfizer Prod Inc compostos azapolicìclicos fundidos com heteroarila
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
BRPI0607838A2 (pt) * 2005-02-24 2009-06-13 Pfizer Prod Inc preparação de uma quinoxalina substituìda de pureza elevada
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
KR20090005305A (ko) * 2006-03-27 2009-01-13 화이자 프로덕츠 인크. 바레니클린 표준물질 및 불순물 제어
EP2012757A2 (en) * 2006-04-24 2009-01-14 Pfizer Products Incorporated Asymmetric membranes for drug delivery devices
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
BRPI0718600A2 (pt) * 2006-11-09 2013-12-10 Pfizer Prod Inc Polimorfos de intermediários nicotínicos.
EP2136833B1 (en) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
CA2752073A1 (en) * 2009-02-11 2010-08-19 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
US8178537B2 (en) 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
WO2011031816A2 (en) * 2009-09-11 2011-03-17 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
RU2014103098A (ru) 2011-06-30 2015-08-10 Торэй Индастриз, Инк. Противозудный агент
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
JP7137850B2 (ja) 2017-03-03 2022-09-15 シーティーシー バイオ インク バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
EP4142734A1 (en) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
IL138917A0 (en) * 1998-04-29 2001-11-25 Pfizer Prod Inc Aryl fused azapolycyclic compounds
AU773795B2 (en) * 1999-01-29 2004-06-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
MXPA03010365A (es) * 2001-05-14 2004-03-16 Pfizer Prod Inc Sal citrato de 5,7,14-triazatetraciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma.
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
AU2002365314A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Aryl fused azapolycyclic compounds
MXPA04003807A (es) * 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila

Also Published As

Publication number Publication date
HN1998000177A (es) 1999-02-09
PA8463901A1 (es) 2000-09-29
KR20010033823A (ko) 2001-04-25
WO1999035131A1 (en) 1999-07-15
SI1044189T2 (sl) 2015-05-29
GT199800200AA (es) 2000-06-07
NL300355I1 (nl) 2008-08-01
TNSN98237A1 (fr) 2005-03-15
EG23816A (en) 2007-09-19
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
LU91442I9 (no) 2018-12-31
YU40300A (sh) 2003-10-31
BR9814592B1 (pt) 2010-06-01
IL136727A (en) 2006-06-11
SG102686A1 (en) 2004-03-26
US20020072525A1 (en) 2002-06-13
PE20000053A1 (es) 2000-02-07
BG65058B1 (bg) 2007-01-31
CA2316921C (en) 2004-12-07
TW513412B (en) 2002-12-11
AU753389B2 (en) 2002-10-17
DE122008000038I1 (de) 2008-11-13
DZ2697A1 (fr) 2003-03-29
DE69839131T2 (de) 2009-02-05
BG104561A (en) 2001-01-31
JP2002500218A (ja) 2002-01-08
CN1324013C (zh) 2007-07-04
BR9814592A (pt) 2000-10-17
CA2316921A1 (en) 1999-07-15
NO2006016I2 (no) 2008-10-20
BR9816186B1 (pt) 2009-01-13
CY1107391T1 (el) 2010-07-28
AU9641698A (en) 1999-07-26
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
NZ504482A (en) 2003-01-31
EA003190B1 (ru) 2003-02-27
CN1285821A (zh) 2001-02-28
FR08C0039I1 (no) 2008-11-14
EP1659114A2 (en) 2006-05-24
CZ20002438A3 (cs) 2002-11-13
FR08C0039I2 (fr) 2009-12-18
TR200001840T2 (tr) 2000-12-21
DK1044189T3 (da) 2008-05-13
PL209404B1 (pl) 2011-08-31
CO4810373A1 (es) 1999-06-30
US20020132824A1 (en) 2002-09-19
MY118163A (en) 2004-09-30
DE69839131T3 (de) 2015-05-07
HRP20000445B1 (en) 2009-04-30
PT1044189E (pt) 2008-04-22
AP9801422A0 (en) 1998-12-31
RS50069B (sr) 2009-01-22
HUP0100949A3 (en) 2002-12-28
GT199800200A (es) 2000-06-07
US20020072524A1 (en) 2002-06-13
NO2006016I1 (no) 2006-11-27
OA11428A (en) 2004-05-03
CY2008013I1 (el) 2009-11-04
CN1715280A (zh) 2006-01-04
EP1659114A3 (en) 2007-01-17
CY2008013I2 (el) 2009-11-04
MA26589A1 (fr) 2004-12-20
AR017967A1 (es) 2001-10-24
US20020111350A1 (en) 2002-08-15
DK1044189T4 (en) 2015-03-30
AP1170A (en) 2003-06-30
AU753389C (en) 2007-08-09
NL300355I2 (nl) 2008-11-03
NO20003422L (no) 2000-08-29
SI1044189T1 (sl) 2008-06-30
CZ301925B6 (cs) 2010-08-04
SK9712000A3 (en) 2002-03-05
US6951938B2 (en) 2005-10-04
HRP20050506A2 (en) 2006-03-31
US20070275973A1 (en) 2007-11-29
KR100408138B1 (ko) 2003-12-01
ATE386024T1 (de) 2008-03-15
JP3550359B2 (ja) 2004-08-04
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
EP1044189A1 (en) 2000-10-18
HU230297B1 (hu) 2015-12-28
PL341824A1 (en) 2001-05-07
SA99191123B1 (ar) 2006-10-02
NO319115B1 (no) 2005-06-20
IL136727A0 (en) 2001-06-14
HUS1600018I1 (hu) 2018-05-02
ZA9811911B (en) 2000-06-29
US6897310B2 (en) 2005-05-24
LU91442I2 (fr) 2008-07-21
ME00459B (me) 2011-10-10
IS5514A (is) 2000-05-26
EP1044189B2 (en) 2015-02-25
US6887884B2 (en) 2005-05-03
DE69839131D1 (de) 2008-03-27
SK286886B6 (sk) 2009-07-06
US6410550B1 (en) 2002-06-25
HK1031878A1 (en) 2001-06-29
UA66825C2 (uk) 2004-06-15

Similar Documents

Publication Publication Date Title
NO20003422D0 (no) Arylfusjonerte azapolycykliske forbindelser
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
ID22850A (id) Senyawa-senyawa pirazina
IS5354A (is) Ný efnasambönd
NO994877D0 (no) Kalsilytiske forbindelser
EE200000321A (et) Uudsed ühendid
DE59810818D1 (de) Fügeverbindung
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
ID24571A (id) Senyawa tienopirimidin
IS5208A (is) Efnasambönd
ID20635A (id) Senyawa metalosen
IS5237A (is) Efnasambönd
IS5323A (is) Efnasambönd
ID22983A (id) Senyawa-senyawa fluorometoksimino
NO995007D0 (no) Forbindelser
DE69737634D1 (de) Insektizide oxadiazinverbindungen
SE9702775D0 (sv) Novel compounds
SE9701397D0 (sv) Compounds
SE9701964D0 (sv) Compounds
ID18388A (id) Senyawa-senyawa heterosiklik
ID21202A (id) Senyawa heterosiklik
SE9702200D0 (sv) Novel compounds

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928

Spc suppl protection certif: 2006016

Filing date: 20061117

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928

Spc suppl protection certif: 2006016

Filing date: 20061117

Extension date: 20210928

SPCK Change in the validity period of an spc

Free format text: PROTECTION PERIOD CHANGED TO: 20210928

Spc suppl protection certif: 2006016

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928

Spc suppl protection certif: 2006016